Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002313 · ClinicalTrials.gov registry record · Phase 1

A Study of Nystatin in HIV-Infected Patients

A Phase 1 study of HIV Infections, sponsored by Argus Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
1
Study location

NCT00002313: Completed Phase 1 study of HIV Infections, sponsored by Argus Pharmaceuticals.

NCT00002313 is a Phase 1 study of HIV Infections that has completed, run by Argus Pharmaceuticals. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002313, a Phase 1 study of HIV Infections, has completed, sponsored by Argus Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
1
Study location

Study Summary

To evaluate the clinical toxicity, safety, and potential anti-HIV activity of intravenous nystatin in patients with HIV infection who have completed protocol FDA 103C. To evaluate the safety and potential antiviral activity of intravenous nystatin and oral didanosine (ddI) administered in an alternating regimen in this patient population.

Conditions Studied

HIV Infections

Interventions

  • DRUG Nystatin
  • DRUG Didanosine

Study Locations (1)

Texas

  • Twelve Oaks Hosp - Houston

Trial Details

FieldValue
Phase Phase 1
Argus Pharmaceuticals

3 total trials

What the finished NCT00002313 record still lists

NCT00002313 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Nystatin is the first listed.

NCT00002313 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT00002313 about?

NCT00002313 is a clinical study titled "A Study of Nystatin in HIV-Infected Patients". To evaluate the clinical toxicity, safety, and potential anti-HIV activity of intravenous nystatin in patients with HIV infection who have completed protocol FDA 103C. To evaluate the safety and potential antiviral activity of intravenous nystatin and oral didanosine (ddI) administered in an alterna...

What is the current status of trial NCT00002313?

This trial is currently completed. It is a Phase 1 study.

What conditions does trial NCT00002313 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00002313?

The interventions under investigation include: Nystatin (DRUG), Didanosine (DRUG).

Who is sponsoring clinical trial NCT00002313?

This trial is sponsored by Argus Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002313 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002313, the US trial registry maintained by the National Library of Medicine. NCT00002313 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.